Cargando…

Deferiprone, an iron chelator, alleviates platelet hyperactivity in patients with β-thalassaemia/HbE

BACKGROUND: Hyperfunctional platelets play important roles in thromboembolism in patients with β-thalassaemia/ haemoglobin E (β-thal/HbE). Our previous study revealed ex vivo inhibitory effects of deferiprone on normal platelets. Herein, we aimed to investigate the in vivo effects on platelets in pa...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tran, Ngan Thi, Sutcharitchan, Pranee, Janprasit, Jindaporn, Rojnuckarin, Ponlapat, Morales, Noppawan Phumala, Luechapudiporn, Rataya
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioExcel Publishing Ltd 2022
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9753601/ https://www.ncbi.nlm.nih.gov/pubmed/36544626 http://dx.doi.org/10.7573/dic.2022-7-6

Ejemplares similares

Inhibitory Mechanisms of Lusianthridin on Human Platelet Aggregation
por: Swe, Hla Nu, et al.
Publicado: (2021)

Protective Effect of Lusianthridin on Hemin-Induced Low-Density Lipoprotein Oxidation
por: Thant, Su Wutyi, et al.
Publicado: (2021)

Impaired neutrophil extracellular trap formation in β-thalassaemia/HbE
por: Thubthed, Rattanawan, et al.
Publicado: (2022)

Microparticles from β-thalassaemia/HbE patients induce endothelial cell dysfunction
por: Kheansaard, Wasinee, et al.
Publicado: (2018)

HBB Gene Mutations and Their Pathological Impacts on HbE/β-Thalassaemia in Kuala Terengganu, Malaysia
por: Saad, Hanan Kamel M., et al.
Publicado: (2023)

Effects of combined deferiprone with deferoxamine on right ventricular function in thalassaemia major
por: Alpendurada, Francisco, et al.
Publicado: (2012)

The History of Deferiprone (L1) and the Paradigm of the Complete Treatment of Iron Overload in Thalassaemia
por: Kontoghiorghes, George J., et al.
Publicado: (2020)

Effect of Iron-Chelator Deferiprone on the In Vitro Growth of Staphylococci
por: Kim, Choon-Mee, et al.
Publicado: (2009)

Salmonella Typhimurium and Pseudomonas aeruginosa Respond Differently to the Fe Chelator Deferiprone and to Some Novel Deferiprone Derivatives
por: Ammendola, Serena, et al.
Publicado: (2021)

A FACS Based Case Study on Two HbE-β Thalassaemia Members of a Family, Having Similar Mutational Background
por: Chatterjee, Tridip, et al.
Publicado: (2016)

Impaired Terminal Erythroid Maturation in β(0)-Thalassemia/HbE Patients with Different Clinical Severity
por: Suriyun, Thunwarat, et al.
Publicado: (2022)

Chelation of Thallium (III) in Rats Using Combined Deferasirox and Deferiprone Therapy
por: Salehi, Samie, et al.
Publicado: (2017)

Restoration of correct β(IVS2-654)-globin mRNA splicing and HbA production by engineered U7 snRNA in β-thalassaemia/HbE erythroid cells
por: Nualkaew, Tiwaporn, et al.
Publicado: (2019)

Cost–Utility Analysis of Deferiprone for the Treatment of β-Thalassaemia Patients with Chronic Iron Overload: A UK Perspective
por: Bentley, Anthony, et al.
Publicado: (2013)

Efficacy and safety of deferiprone (Ferriprox), an oral iron-chelating agent, in pediatric patients
por: Won, Sung Chul, et al.
Publicado: (2010)

Chelation Therapy with Oral Solution of Deferiprone in Transfusional Iron-Overloaded Children with Hemoglobinopathies
por: Makis, Alexandros, et al.
Publicado: (2013)

Erratum to: Cost–Utility Analysis of Deferiprone for the Treatment of β-Thalassaemia Patients with Chronic Iron Overload: A UK Perspective
por: Bentley, Anthony, et al.
Publicado: (2013)

Novel Antidepressant-Like Properties of the Iron Chelator Deferiprone in a Mouse Model of Depression
por: Uzungil, Volkan, et al.
Publicado: (2022)

Curcumin Extract for Prevention of Type 2 Diabetes
por: Chuengsamarn, Somlak, et al.
Publicado: (2012)

Single-center retrospective study of the effectiveness and toxicity of the oral iron chelating drugs deferiprone and deferasirox
por: Olivieri, Nancy F., et al.
Publicado: (2019)

Hb E/beta-thalassaemia: a common & clinically diverse disorder
por: Olivieri, Nancy F., et al.
Publicado: (2011)

Moyamoya syndrome in a child with HbEβ‐thalassemia
por: Zahra, Akmal, et al.
Publicado: (2022)

Differential Thermal Stability and Oxidative Vulnerability of the Hemoglobin Variants, HbA(2) and HbE
por: Chakrabarti, Abhijit, et al.
Publicado: (2013)

Randomized controlled trials of iron chelators for the treatment of cardiac siderosis in thalassaemia major
por: Baksi, A. John, et al.
Publicado: (2014)

Direct Oral Anticoagulants and Travel-related Venous Thromboembolism
por: Chamnanchanunt, Supat, et al.
Publicado: (2018)

Correction: Single-center retrospective study of the effectiveness and toxicity of the oral iron chelating drugs deferiprone and deferasirox
Publicado: (2019)

Synergistic antioxidant action of Phikud Navakot ameliorates hydrogen peroxide-induced stress in human endothelial cells
por: Nalinratana, Nonthaneth, et al.
Publicado: (2014)

Predictive SNPs for β(0)-thalassemia/HbE disease severity
por: Munkongdee, Thongperm, et al.
Publicado: (2021)

Abstract 40: Adrenal insufficiency in patients with HbE/Beta thalassemia
por: Singh, Arijit, et al.
Publicado: (2022)

Combination Iron Chelation Therapy with Deferiprone and Deferasirox in Iron-Overloaded Patients with Transfusion-Dependent β-Thalassemia Major
por: Karami, Hossein, et al.
Publicado: (2017)

Long-Term Neuroradiological and Clinical Evaluation of NBIA Patients Treated with a Deferiprone Based Iron-Chelation Therapy
por: Romano, Nicola, et al.
Publicado: (2022)

Deferiprone−Resveratrol Hybrid, an Iron-Chelating Compound, Acts as an Antimalarial and Hepatoprotective Agent in Plasmodium berghei-Infected Mice
por: Chuljerm, Hataichanok, et al.
Publicado: (2022)

The Vital Role Played by Deferiprone in the Transition of Thalassaemia from a Fatal to a Chronic Disease and Challenges in Its Repurposing for Use in Non-Iron-Loaded Diseases
por: Kontoghiorghes, George J.
Publicado: (2023)

Status of HbE variant among Rabha tribe of West Bengal, India
por: Bhattacharyya, Deboshree M., et al.
Publicado: (2015)

A decision support scheme for beta thalassemia and HbE carrier screening
por: Das, Reena, et al.
Publicado: (2020)

Severe homozygous HbE disease: the first case report from Nepal
por: Bhattarai, Urza, et al.
Publicado: (2023)

Thalidomide-Induced Primary Amenorrhea in a Patient With HbE/Beta-Thalassemia
por: Singha, Arijit, et al.
Publicado: (2023)

Immune dysregulation in extranodal NK/T cell lymphomas: potential roles in pathogenesis and immunotherapy
por: Polprasert, Chantana, et al.
Publicado: (2021)

Comparison of iron chelation effects of deferoxamine, deferasirox, and combination of deferoxamine and deferiprone on liver and cardiac T2* MRI in thalassemia maior
por: Ansari, Shahla, et al.
Publicado: (2017)

Approaching low liver iron burden in chelated patients with non-transfusion-dependent thalassemia: the safety profile of deferasirox
por: Taher, Ali T, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_e679mqhdfdp1371p6tgu6ct2nt